Lazcluze

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to **EPAR - Procedural steps taken and scientific information after authorisation (archive)**.

Application number	Scope	Opinion/ Notification [1] issued on	Commission Decision Issued[2] / amended on	Product Information affected[3]	Summary
Variation type II /	C.I HUMAN AND VETERINARY MEDICINAL	12/02/2026		SmPC	SmPC new text The sub-section 'Description of

[1] Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.
[2] A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.
[3] SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

EMA/VR/0000315717	PRODUCTS - C.I.4 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilance data - Accepted Update of section 4.8 of the SmPC in order to add information regarding elevations in alkaline phosphatase and bilirubin with lazertinib monotherapy within the 'hepatotoxicity' subsection, based on a cumulative safety review. The RMP version 2.1 has also been agreed.				selected adverse reactions - hepatotoxicity' in the SmPC section 4.8 has been updated to include that isolated reports of alkaline phosphatase increased and prolonged elevated bilirubin have been identified with lazertinib monotherapy. For more information, please refer to the Summary of Product Characteristics.
Variation type II / EMA/VR/0000261993	This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.4 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilance data - Accepted Update of sections 4.2, 4.4 and 4.8 of the SmPC for Rybrevant and Lazcluze in order to include updated information on enhanced dermatologic management regimen as prophylactic treatment to reduce the risk of dermatological toxicities during treatment,	18/09/2025		SmPC and PL	SmPC new text Based on the results of a phase 2 study in patients treated with amivantamab in combination with lazertinib assessing the use of prophylactic therapy with an oral antibiotic, a topical antibiotic on the scalp, a moisturiser on the face and whole body and an antiseptic on hands and feet, recommendations on dermatologic management have been strenghten in sections 4.2 and 4.4 of the SmPC of both products. Prophylactic therapy with oral and topical antibiotics is recommended to reduce the risk and severity of skin and nail reactions in patients receiving amivantamab and lazertinib at treatment initiation. Non comedogenic skin moisturiser (ceramide based or other formulations that provide long lasting skin hydration and exclude drying agents are preferred) on the face and whole body (except scalp) and chlorhexidine solution to wash hands and feet are

	based on results from study 61186372NSC2007. Study 61186372NSC2007 (COCOON) is a Phase 2, open-label, randomized trial evaluating the impact of enhanced versus standard dermatologic management on selected dermatologic adverse events among patients with locally advanced or metastatic EGFR-mutated NSCLC treated first-line with amivantamab + lazertinib. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to introduce minor corrections to the PI for Lazcluze and Rybrevant.				also recommended beginning on day1 and continued foe the duration of treatment. For more information, please refer to the Summary of Product Characteristics.
Variation type II / EMA/VR/0000253354	This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.4 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilance data - Accepted Update of section 5.1 of the SmPC in order to provide final Overall Survival (OS) data following Rybrevant extension of indication procedure (EMEA/H/C/005454/II/0013), and Lazcluze MAA approval	19/06/2025		SmPC	SmPC new text OS, intracranial ORR and DOR data were updated in section 5.1 of the SmPC based on final results from the Mariposa study (a pivotal randomized, open-label, Phase 3 study that compares the efficacy and safety of the combination of amivantamab and lazertinib (Arm A) versus osimertinib monotherapy (Arm B) and lazertinib monotherapy (Arm C) in participants with EGFRm NSCLC): The final analysis of OS demonstrated a statistically significant improvement in OS for Rybrevant in combination with lazertinib compared to Osimertinib and the intracranial ORR and DOR were updated. For more information, please refer to the Summary of Product Characteristics.

	(EMEA/H/C/006074/0000), and based on final results from study 73841937NSC3003 (MARIPOSA); this is a pivotal randomized, open-label, Phase 3 study that compares the efficacy and safety of the combination of amivantamab and lazertinib (Arm A) versus osimertinib monotherapy (Arm B) and lazertinib monotherapy (Arm C) in participants with EGFRm NSCLC.				
Variation type IB / EMA/VR/0000257464	This was an application for a group of variations. B.I.b.1 Change in the specification parameters and/or limits of an active substance, starting material / intermediate / reagent used in the manufacturing process of the active substance - B.I.b.1.z Other changes - Accepted B.II.d.2 Change in test procedure for the finished product - B.II.d.2.a Minor changes to an approved test procedure - Accepted A. ADMINISTRATIVE CHANGES - A.4 Change in the name and/or address of: a manufacturer (including where relevant quality control testing sites); or an ASMF holder; or a supplier of the active substance, starting material, reagent or intermediate used in the manufacture of the active substance (where specified in the technical dossier) where no Ph. Eur. Certificate of Suitability is part of the approved dossier; or	12/06/2025			

	a manufacturer of a novel excipient (where specified in the technical dossier) - Accepted B.II.b.1 Replacement or addition of a manufacturing site for part or all of the manufacturing process of the finished product - B.II.b.1.a Secondary packaging site - Accepted				
Variation type IB / EMA/VR/0000258318	C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.z Other variation - Accepted C.I.z - To provide and updated Environmental Risk Assessment Report (ERA).	11/04/2025			
PSUR / EMA/PSUR/0000296610					Maintenance